Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LJPC | Common Stock | Award | $619 | +148 | +2.3% | $4.18 | 6.58K | Jan 14, 2022 | Direct | F1 |
holding | LJPC | Common Stock | 9.61M | Jan 14, 2022 | By LP | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LJPC | Employee Stock Option (Right to Buy) | Award | $0 | +148 | $0.00 | 148 | Jan 14, 2022 | Common Stock | 148 | $4.92 | Direct | F3 |
Id | Content |
---|---|
F1 | These shares were acquired on 1/14/2022 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
F2 | The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Tang Capital Management, LLC ("TCM") is the general partner of TCP. Michael Hearne is the Chief Financial Officer of La Jolla Pharmaceutical Company, as well as the Chief Financial Officer of TCM. Mr. Hearne has a pecuniary interest in the shares beneficially held by TCP. |
F3 | The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of the grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |